2. Signaling Pathways
  3. Neuronal Signaling
  4. α-synuclein

α-synuclein

α-Syn

α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-synuclein regulates synaptic vesicle trafficking and subsequent neurotransmitter release. Genetics and neuropathology studies link α-synuclein to Parkinson's disease (PD) and other neurodegenerative disorders. Accumulation of misfolded oligomers and larger aggregates of α-synuclein defines multiple neurodegenerative diseases called synucleinopathies, but the mechanisms by which α-synuclein acts in neurodegeneration are unknown.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-16009
    Buntanetap
    		Inhibitor 98.11%
    Buntanetap ((+)-Phenserine) is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease.
    Buntanetap
  • HY-132845
    Utreloxastat
    		99.69%
    Utreloxastat (PTC857) is a compound used for the research of the disorders including α-synucleinopathies, tauopathies, Amyotrophic lateral sclerosis (ALS), traumatic brain injury, and ischemic-reperfusion related injuries (patent WO2020081879A2, example A1).
    Utreloxastat
  • HY-124876
    SynuClean-D
    		99.89%
    SynuClean-D (SC-D) is an inhibitor of α-synuclein aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease.
    SynuClean-D
  • HY-N0901A
    Corynoxine B
    		Inducer 99.76%
    Corynoxine B is a natural alkaloid and autophagy inducer that can improve Mn induced cellular autophagy dysregulation and enhance clearance of alpha synuclein (alpha syn) in Parkinson's disease mice[1][3].
    Corynoxine B
  • HY-107811
    Harmol
    		Inhibitor 99.77%
    Harmol is a TFEB activator, an orally active monoamine oxidase inhibitor that has anti-tumor, anti-depressant, and anti-aging effects. Harmol can induce cell mitosis, autophagy and apoptosis. Harmol promotes the degradation of α-synuclein through the regulation of the autophagy-lysosomal pathway, improving motor deficits in mouse models of Parkinson's disease.
    Harmol
  • HY-160116
    α-Synuclein aggregate binder 1
    		Inhibitor 98.11%
    α-Synuclein aggregate binder 1 (Compound C05-05) is a collective binder and an inhibitor for α-synuclein aggregation. α-Synuclein aggregate binder 1 is utilized in Positron Emission Tomography (PET) imaging and fluorescence microscope, that can diagnose and ameliorate the neurodegenerative disease.
    α-Synuclein aggregate binder 1
  • HY-121152
    Chiisanoside
    		Inhibitor
    Chiisanoside exhibits neuroprotective, anticancer, antidepressant, anti-inflammatory, anti-obesity and anti-platelet activities. Chiisanoside inhibits tumor growth in H22 xenograft mouse model, through immunoregulation, induction of apoptosis and inhibition of angiogenesis. Chiisanoside attenuates Parkinson’s disease through regulation of Parkin/ZNF746/PGC-1α axis, and promotion of mitochondrial biogenesis.
    Chiisanoside
  • HY-N0901AR
    Corynoxine B (Standard)
    		Inducer
    Corynoxine B (Standard) is the analytical standard of Corynoxine B. This product is intended for research and analytical applications. Corynoxine B is a natural alkaloid and autophagy inducer that can improve Mn induced cellular autophagy dysregulation and enhance clearance of alpha synuclein (alpha syn) in Parkinson's disease mice.
    Corynoxine B (Standard)
  • HY-155021
    PROTAC α-synuclein degrader 5
    		Degrader 99.71%
    PROTAC α-synuclein degrader 5 is a highly selective small-molecule degraders (PROTAC) of α-synuclein aggregates, with an DC50 of 7.51 μM and the highest degradation rate Dmax of 89%. PROTAC α-synuclein degrader 5 contains probe molecule sery308 and E3 ligase ligands. PROTAC α-synuclein degrader 5 can be used for neurological disease research.
    PROTAC α-synuclein degrader 5
  • HY-Y0790
    Cuminaldehyde
    		Inhibitor 99.03%
    Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC50= 0.00085 mg/mL), α-glucosidase (IC50=0.5 mg/mL) and lipoxygenase (IC50=1370 μM). Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases.
    Cuminaldehyde
  • HY-136001
    PROTAC α-synuclein degrader 3
    		Degrader 99.35%
    PROTAC α-synuclein degrader 3 (compound 5) is a potent and selective PROTAC α-synuclein degrader. PROTAC α-synuclein degrader 3 can be used in research of Parkinson's disease.
    PROTAC α-synuclein degrader 3
  • HY-120475A
    PBT434 mesylate
    		Inhibitor 99.92%
    PBT434 methanesulfonate is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 methanesulfonate can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 methanesulfonate inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 methanesulfonate prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 methanesulfonate has the potential for the research of Parkinson’s disease (PD).
    PBT434 mesylate
  • HY-P99405
    Prasinezumab
    		Inhibitor 99.90%
    Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research.
    Prasinezumab
  • HY-157839
    PROTAC α-synuclein degrader 6
    		Degrader 99.04%
    PROTAC α-synuclein degrader 6 (compound T3) is a PROTAC degrader of α-synuclein and tau, with EC50 of 1.57 μM and 4.09 μM, respectively. PROTAC α-synuclein degrader 6 plays an important role in neurodegenerative diseases (NDs) research.
    PROTAC α-synuclein degrader 6
  • HY-P99356
    Cinpanemab
    		Inhibitor
    Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease.
    Cinpanemab
  • HY-145580
    Minzasolmin
    		99.20%
    Minzasolmin is an alpha-synuclein oligomerization inhibitor.
    Minzasolmin
  • HY-115038
    ELN484228
    		99.50%
    ELN484228 is a blocker of α-synuclein which is a key protein in Parkinson’s disease.
    ELN484228
  • HY-P3140A
    α-Synuclein (61-75) (TFA)
    		99.62%
    α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD).
    α-Synuclein (61-75) (TFA)
  • HY-145580A
    (S)-Minzasolmin
    (S)-Minzasolmin is an isomer of minzasolmin (HY-145580), an inhibitor of α-synuclein oligomerization.
    (S)-Minzasolmin
  • HY-156435
    tau protein/α-synuclein-IN-1
    		Inhibitor
    tau protein/α-synuclein-IN-1 is a dual inhibitor of tau protein and α-synuclein. tau protein/α-synuclein-IN-1 reduces α-syn inclusions development in M17D neuroblastoma cells. tau protein/α-synuclein-IN-1 can be used in study Alzheimer’s disease.
    tau protein/α-synuclein-IN-1
Cat. No. Product Name / Synonyms Application Reactivity